Stock 1AD ADALTA LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

AdAlta Limited Share Price

Equities

1AD

AU0000001AD2

Biotechnology & Medical Research

Market Closed - Australian S.E.
Other stock markets
 04:00:10 26/04/2024 BST 		5-day change 1st Jan Change
0.031 AUD +6.90% Intraday chart for AdAlta Limited +10.71% +29.17%
04-08 AdAlta Explores Cancer Immunotherapies Joint Venture for Western Market MT
02-26 AdAlta Limited Reports Earnings Results for the Half Year Ended December 31, 2023 CI

Financials

Sales 2022 2.75M 1.8M 144M Sales 2023 3.47M 2.27M 181M Capitalization 8.8M 5.75M 460M
Net income 2022 -6M -3.92M -314M Net income 2023 -4M -2.61M -209M EV / Sales 2022 4.47 x
Net cash position 2022 4.66M 3.04M 244M Net cash position 2023 776K 507K 40.56M EV / Sales 2023 2.31 x
P/E ratio 2022
-2.48 x
P/E ratio 2023
-1.57 x
Employees 10
Yield 2022 *
-
Yield 2023
-
Free-Float 63.48%
More Fundamentals * Assessed data

Chart AdAlta Limited

Dynamic Chart

Latest news about AdAlta Limited

AdAlta Explores Cancer Immunotherapies Joint Venture for Western Market MT
AdAlta Limited Reports Earnings Results for the Half Year Ended December 31, 2023 CI
AdAlta-La Trobe University Collab Discovers New i-Bodies for Malaria Treatment; Shares Climb 4% MT
Adalta Posts Upbeat Results from Phase I Trial of Fibrotic Disease Drug MT
AdAlta Raises AU$1.7 Million Via Oversubscribed Placement; Shares Down 9% MT
AdAlta to Seeks AU$1.2 Million from Share Placement MT
AdAlta Receives AU$2.4 Million R&D Tax Rebate MT
Adalta Completes Enrollment for Phase 1 Study on Fibrotic Disease Medication; Shares Fall 9% MT
AdAlta Limited Reports Earnings Results for the Full Year Ended June 30, 2023 CI
Adalta Carries Out First Dosing in Phase One Extension Study of Fibrotic Disease Medication; Shares Jump 4% MT
AdAlta Raises AU$1.9 Million Via Oversubscribed Shortfall Facility MT
AdAlta Secures Ethics Approval for Phase One Clinical Trial MT
AdAlta Raises AU$1.3 Million Via Rights Offer MT
Adalta Limited Announces Retirement of Elizabeth Mccall as Non-Executive Director CI
AdAlta Limited Reports Earnings Results for the Half Year Ended December 31, 2022 CI
More news

Analyst Recommendations on AdAlta Limited

Australian Shares in the Red as US Fed Likely to Continue Rate Hikes MT
More recommendations

Press releases AdAlta Limited

AdAlta delivers positive Phase I Extension Study results for AD-214 AQ
AdAlta closes oversubscribed $1.65 million raise AQ
AdAlta making material progress on partnering talks AQ
AdAlta says new AD-214 dosing models enhance partnering potential AQ
AdAlta completes enrolment for AD-214 fibrosis safety trial AQ
More press releases

Quotes and Performance

1 day+6.90%
1 week+10.71%
Current month+14.81%
1 month+24.00%
3 months+34.78%
6 months+40.91%
Current year+29.17%
More quotes

Highs and lows

1 week
0.03
Extreme 0.028
0.03
1 month
0.03
Extreme 0.025
0.04
Current year
0.02
Extreme 0.019
0.04
1 year
0.02
Extreme 0.017
0.05
3 years
0.02
Extreme 0.017
0.16
5 years
0.02
Extreme 0.017
0.27
10 years
0.02
Extreme 0.017
0.40
More quotes

Managers and Directors - AdAlta Limited

Managers TitleAgeSince
Timothy Oldham CEO
 Chief Executive Officer - 13/10/19
Mick Foley CTO
 Chief Tech/Sci/R&D Officer - -
Dallas Hartman COO
 Chief Operating Officer - 08/10/17
Members of the board TitleAgeSince
Robert Peach BRD
 Director/Board Member 68 13/11/16
Paul MacLeman CHM
 Chairman 58 15/04/15
Timothy Oldham CEO
 Chief Executive Officer - 13/10/19
More insiders

Quotes

Date Price Change Volume
26/04/24 0.031 +6.90% 318,998
24/04/24 0.029 0.00% 344,254
23/04/24 0.029 +3.57% 116,689
22/04/24 0.028 0.00% 957,491
19/04/24 0.028 +3.70% 2,964,789

Delayed Quote Australian S.E., April 26, 2024 at 04:00 am

More quotes

Company Profile

AdAlta Limited is an Australia-based clinical-stage drug discovery company. The Company is engaged in the development of therapeutic products from its i-body platform. The Company has five active development programs ranging from discovery to Phase II clinical trials with applications in the fields of inflammation/fibrosis and immuno-oncology. Its lead product, AD-214, is an antibody therapeutic for the treatment of fibrotic diseases, including lung fibrosis (specifically Idiopathic Pulmonary Fibrosis (IPF) and Interstitial Lung Disease (ILD)), kidney fibrosis, eye fibrosis and some cancers. Chimeric Antigen Receptor (CAR) cell therapies involve modification of a patient’s immune cells (T cells, NK cells, macrophages and other) so that they produce a CAR on the cell surface that enables the patient’s immune system to recognize and kill diseased cells such as cancer. It develops i-body enabled PET (i-PET) imaging agents for use in immuno-oncology. It evaluates several CXCR4 i-bodies.
Sector
Biotechnology & Medical Research
Calendar
22/08/2024 - Q4 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
ADALTA LIMITED Stock AdAlta Limited
+29.17% 10.63M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.28B
ARGENX SE Stock argenx SE
+1.69% 22.15B
BIONTECH SE Stock BioNTech SE
-17.37% 21.02B
GENMAB A/S Stock Genmab A/S
-9.30% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.73B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. 1AD Stock